SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Pyth Network is a decentralised oracle network designed to provide real-time financial market data to decentralised applications (dApps) across multiple blockchains. It allows developer to secure smart contracts with reliable, low-latency market data from institutional sources, and build apps with high-fidelity oracle feeds designed for mission-critical systems.

Pyth Network

Pyth Network is trending due to its recently announced token buyback program, which is backed by revenue generated from its Pyth Pro services. This development is fueling community discussions about the project's sustainable tokenomics and its growing role as a significant oracle in the crypto ecosystem, particularly within the Real World Asset (RWA) narrative.

What is the project about? Pepe is a community based meme token surround the iconic meme Pepe the frog. Pepe aims to leverage the power of such an iconic meme to become the most memeable memecoin in existence.   What makes your project unique? Pepe is here to make memecoins great again. Ushering in a new paradigm for memecoins, Pepe represents the memecoin in it's purest simplicity. With zero taxes, liquidity locked forever, and contract immutable, Pepe is for the people, forever. Pepe is about culture, rallying together a community to have fun and enjoy memes, fueled purely by memetic power.   History of your project. Pepe was stealth launched on Friday, April 14th, 2023.   What’s next for your project? Pepe will focus on developing a tight-knit community around the token and building resources to enrich the communities knowledge and success in crypto through a token gated group, newsletter, and more tools.   What can your token be used for? Pepe can be used to speculate on the power of memes, and does not pretend to be anything more.

Pepe

PEPE crypto is trending with high community engagement as traders eye a potential breakout, aiming for significant gains. Despite mixed sentiment following recent volatility, many holders are actively accumulating positions, anticipating an "alt season" to fuel the meme coin's next major run.

Bonk is a dog-themed memecoin on the Solana blockchain, launched on Christmas Day 2022 to revitalize the Solana community following the FTX collapse. Created by an anonymous team of 22 Solana developers and builders, Bonk distributed 50% of its total 100 trillion token supply via airdrop to community members including NFT collectors, developers, and artists.   The project positions itself as "the first Solana dog coin for the people, by the people," explicitly rejecting venture capital backing in favor of grassroots community ownership. What sets Bonk apart from other memecoins is its combination of fair launch mechanics, extensive ecosystem integration, and active deflationary strategy.   Built on Solana, BONK benefits from fast transaction speeds and low fees that make it practical for everyday use. Native products include LetsBonk.fun (a memecoin launchpad that briefly became Solana's market leader in 2025, surpassing Pump.fun with over 78% market share), BonkSwap (a decentralized exchange) and BonkBot (a Telegram trading bot with built-in burn mechanics).   BONK is available across 10 blockchain networks and listed on major exchanges including Binance, Coinbase, Kraken, and Robinhood. Governance is handled by BonkDAO, which holds 15% of the token supply and makes decisions through on-chain voting.   The community has organized several major burn events, most notably the December 2024 BURNmas campaign that destroyed 1.69 trillion tokens worth over $50 million. In September 2025, Nasdaq-listed Safety Shot, Inc. formed BONK Holdings LLC and acquired over 2.5% of the circulating supply (valued at $55-63 million), making BONK one of the first memecoins to attract formal corporate treasury adoption. Core contributor Nom was appointed to Safety Shot's board, and the company holds a 10% revenue share in LetsBonk.fun.  As with all memecoins, BONK is a highly speculative asset with substantial volatility. Its value is primarily driven by community sentiment, social media momentum, and meme culture rather than traditional utility.   The anonymous team, while common in the memecoin space, means investors should exercise appropriate caution. Despite these risks, Bonk has established itself as one of the most successful community-driven tokens in the Solana ecosystem, approaching 1 million unique holders and expanding from a simple memecoin into meaningful DeFi infrastructure.

BONK

BONK is trending amidst excitement surrounding the launch of its first ETP in Europe and the imminent 1 trillion token burn as the community nears one million holders. This is fueling strong community discussions about its expanding utility, including a new kill-to-earn arena with token burns and zero-fee trading platforms, with many anticipating significant future growth in an evolving alt/meme coin season.

Avalanche is a high throughput smart contract blockchain platform. Validators secure the network through a proof-of-stake consensus protocol. It is said to be fast, low cost, and environmental friendly.

Avalanche

Avalanche (AVAX) is trending amidst highly polarized sentiment, driven by significant institutional developments and an active community. Conversations center on BlackRock leveraging AVAX subnets for real-world asset tokenization and Bitwise filing for a spot AVAX ETF with staking, signaling strong future adoption. Despite this long-term optimism and network upgrades, many holders express frustration with recent price performance, attributing current dips to broader market conditions while others see it as an accumulation opportunity.

What is Amp?  Amp is described as the new digital collateral token offering instant, verifiable assurances for any kind of value transfer. Using Amp, networks like Flexa can quickly and irreversibly secure transactions for a wide variety of asset-related use cases.  How does Amp work?  Amp claims to offer a straightforward but versatile interface for verifiable collateralization through a system of collateral partitions and collateral managers. Where collateral partitions can be designated to collateralize any account, application, or even transaction, and carry balances which are directly verifiable on the Ethereum blockchain, collateral managers are smart contracts that can lock, release, and redirect collateral in these partitions as needed in order to support value transfer activities. Amp supports a wide variety of use cases for collateralization, and also introduces the concept of predefined partition strategies, which can enable special capabilities such as collateral models through which tokens can be staked without ever leaving their original address.

AMP Token

AMP Token is actively trending due to a recent price surge, igniting a polarized debate within the community. Enthusiasts are highlighting its established real-world utility through Flexa's partnerships with major retailers and anticipating future growth from potential regulatory clarity. Conversely, a significant portion of investors view the rally as another temporary 'pump and dump,' expressing deep skepticism about sustained gains and past market manipulation.

Memecoin on Injective taken over by the community.

Nonja

The crypto community is buzzing about $NONJA, viewing it as a prime meme coin within the Injective ecosystem. Intense anticipation for Injective's ecosystem growth, driven by potential upcoming ETFs, positions $NONJA as a high-leverage opportunity. Its strong, active community, robust liquidity, and successful NFT collections are frequently cited as drivers for significant future gains.

English version Introducing SWFTCoin (SWFTC) $SWFTC: Powering SWFT Blockchain and AI Services (SWFTGPT)  SwftCoin ($SWFTC) is the native utility token driving SWFT Blockchain's AI-powered ecosystem, SWFTGPT, and the first ever AI token featured on Coinbase. SWFTGPT is also the first domain-specific LLM for crypto.  SwftCoin key features include: 50% Reduced Transaction Fees: Lower costs on all transactions. AI Service Payments: Use $SWFTC to access SWFTGPT. Tools include expert market analysis,  predictions, and intelligent trading solutions.  Membership Benefits: Unlock premium features and AI agent services within SWFTGPT. AI-Powered Swaps: Enable precise, fast cross-chain transactions and analytics. SWFT Blockchain combines AI innovation with blockchain infrastructure, simplifying crypto trading while enhancing functionality through $SWFTC.   Chinese version $SWFTC：驱动 SWFT Blockchain 和 AI 服务（SWFTGPT） SwftCoin ($SWFTC) 是 SWFT Blockchain 的原生实用代币，为其 AI 驱动的生态系统 SWFTGPT 提供支持，同时也是 Coinbase 上首个 AI 代币。SWFTGPT 也是首个专注于加密领域的特定领域大型语言模型 (LLM)。 SwftCoin 的主要功能包括： 1、50% 交易费减免：降低所有交易成本。 2、AI 服务支付：使用 $SWFTC 访问 SWFTGPT 工具，包括专家市场分析、预测以及智能交易解决方案。 3、会员权益：解锁 SWFTGPT 的高级功能和 AI 代理服务。 4、AI 驱动的闪兑：实现精准快速的跨链交易和数据分析。 SWFT Blockchain 将 AI 创新与区块链基础设施结合，通过 $SWFTC 简化加密交易，并提升其功能性。

SwftCoin

SWFTC is actively trending amid widespread community excitement, primarily driven by persistent rumors of new major exchange listings, notably Coinbase, and noticeable increases in trading volume. The community is emphasizing its core utility, including an AI-integrated exchange and crucial cross-chain bridging technology, with many anticipating substantial "altseason" gains. Discussions highlight its fully diluted supply and perceived undervaluation, positioning it as a key infrastructure play in the evolving multi-chain crypto landscape.

Ancient8 is the gaming L2 on Ethereum backed by Dragonfly, Pantera, Hashed, Coinbase Ventures and Makers Fund. Ancient8 offers a suite of Web3 gaming infrastructure tools that serve as the distribution and marketing channel for games globally.

Ancient8

Ancient8 (A8 CRYPTO) is actively trending, fueled by speculative interest following its recent Coinbase listing and its position as a gaming token within a potentially heating crypto sector. The community is sharply divided, with many anticipating a significant upward move due to its low market cap and limited circulation, while others raise strong concerns regarding its legitimacy and potential for a rug pull.

eXoZymes, Inc. is a development stage synthetic biochemical company. Its synthetic biology platform would enable the scalable exploration of many molecules and properties found in nature. The company was founded by Tyler Korman and Paul Opgenorth in April 2019 and is headquartered in Monrovia, NV.

eXoZymes Inc.

eXoZymes is trending as a core industry partner in a significant NSF-funded initiative to advance modular cell-free biomanufacturing, highlighting its unique AI-engineered platform. This development, alongside a demonstrated 100x scale-up and high-efficiency production of key compounds like NCT, fuels community discussion about the company leading a "paradigm shift" in sustainable biochemical manufacturing. Investors are actively discussing its potential to transform industries like nutraceuticals and pharmaceuticals by de-risking commercialization through its innovative approach.

WidePoint Corp. engages in the provision of Technology Management as a Service (TMaaS). The firm is involved in providing managed services for government and commercial clients that include identity management, secure mobility managed services, telecom lifecycle management, digital billing and analytics, and Information Technology as a service (ITaaS). The company was founded on May 30, 1997 and is headquartered in Fairfax, VA.

Widepoint Corp

Widepoint Corp is trending as conversation centers on its pivotal DHS CWMS 3.0 contract and recently achieved FedRAMP Authorized status, signaling its deepened role in government cybersecurity. While many in the community view the company as deeply undervalued given its substantial contract backlog and strategic deals like a recent major SaaS agreement, persistent concerns about profitability and competition temper enthusiasm. The key discussion points revolve around management's ability to convert growing federal and commercial engagements into consistent positive earnings.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Eldred Rock Partners LLC Has $11.64 Million Position in Novartis AG $NVS

Eldred Rock Partners LLC lifted its holdings in shares of Novartis AG (NYSE:NVS - Free Report) by 12.2% in the third quarter, according to its most recent filing with the SEC. The firm owned 90,753...

Moody Lynn & Lieberson LLC Acquires 16,752 Shares of Novartis AG $NVS

Moody Lynn & Lieberson LLC increased its holdings in shares of Novartis AG (NYSE:NVS - Free Report) by 731.8% during the 3rd quarter, according to its most recent Form 13F filing with the Securities...

<ul class="summary-bullets"><li>More medicines are slated for price hikes in 2026, with increases tracking around recent inflation levels.</li><li>Only a few drugs are seeing price cuts as they are largely tied to government-negotiated pricing.</li><li>Additional changes are likely in January, the peak period for annual drug price updates.</li></ul><p>Pfizer is reportedly leading a new wave of planned U.S. drug price increases for 2026, with the company set to raise list prices on around 80 medicines even as the White House steps up pressure on drugmakers to curb costs.</p><p>Most of Pfizer’s planned hikes are below 10%, though Comirnaty is set for a 15% increase. The company’s average list price rise for innovative medicines and vaccines will be below the overall inflation rate to support research and rising business costs, Reuters&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.reuters.com/business/healthcare-pharmaceuticals/drugmakers-raise-us-prices-350-medicines-despite-pressure-trump-2025-12-31/">reported</a>, citing data from research firm 3 Axis Advisors.</p><h2 class="st-heading-2"><strong>Price Increases Outnumber Cuts</strong></h2><p>There are more drugs on the list of planned price increases for 2026 than at the same time last year, when companies were planning raises on more than 250 medicines. The median planned increase is around 4%, in line with 2025, and is based on list prices before any rebates or discounts.</p><p>Drugmakers also plan a limited set of list price cuts. Nine medications are anticipated to be cut back. A 40% or more decrease is slated for Boehringer Ingelheim’s diabetes treatment Jardiance. Eli Lilly, which markets Jardiance along with Boehringer Ingelheim, was also involved in the pricing actions based on lower government negotiated prices for 2026 Medicare prices, according to the Reuters report.&nbsp;</p><h2 class="st-heading-2"><strong>GSK Joins Price-Rise List&nbsp;</strong></h2><p>European drugmaker GSK is set to raise prices of about 20 drugs and vaccines by 2% to 8.9%. The company said the increases are necessary to maintain scientific innovation.</p><p>January is the top month for drugmakers to make annual price adjustments, indicating that more list price increases and selective decreases may be on the way as the industry tries to find a balance on pricing that makes sense politically and publicly.</p><h2 class="st-heading-2"><strong>Trump Deals With Major Drugmakers</strong></h2><p>The planned price increases come amid pressure from U.S. President Donald Trump to lower U.S. prescription drug costs to levels paid in other wealthy nations. The government&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/trump-strikes-new-drug-price-deals-with-roche-novartis-merck-and-other-pharma-giants/cLe0duBREtP">earlier this month widened “most-favored-nation” pricing deals</a> with big drug companies, taking to 14 the number that have agreed to them so far.&nbsp;</p><p>Firms that have signed on include Pfizer, Sanofi, Boehringer Ingelheim, Novartis and GSK, among others. The agreements cover some drugs in the Medicaid program and a government-backed direct-to-patient website.</p><h2 class="st-heading-2"><strong>How Did Stocktwits Users React?</strong></h2><p>On Stocktwits, retail sentiment for Pfizer was ‘bearish’ amid ‘low’ message volume.</p><figure class="image"><img style="aspect-ratio:972/146;" src="https://news.stocktwits-cdn.com/pfe_ss_png_b2d4a2337b.webp" alt="pfe ss.png" width="972" height="146"><figcaption>PFE sentiment and message volume as of December 31| Source: Stocktwits</figcaption></figure><p>One user said, “Going higher. Good upside in 2026.&nbsp; Today’s move up is the start.”</p><p><stembedurl>https://stocktwits.com/Mukulu2025/message/640483647</stembedurl></p><p><a href="https://stocktwits.com/symbol/PFE">Pfizer’s stock</a> has risen 1% so far in 2025.</p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

In this photo illustration, Pfizer’s logo is on a smartphone with an economic stock exchange index graph in the background. (Photo Illustration by Budrul Chukrut/SOPA Images/LightRocket via Getty Images)

Pfizer Leads New Wave Of 2026 US Drug Price Hikes Despite Trump’s Drug Cost Crackdown: Report

Drugmakers are outlining 2026 list price changes, with most adjustments typically announced in January.

Equity

HM Payson & Co. Acquires 10,000 Shares of Novartis AG $NVS

HM Payson & Co. increased its holdings in shares of Novartis AG (NYSE:NVS - Free Report) by 306.6% in the 3rd quarter, according to the company in its most recent filing with the Securities...

Archford Capital Strategies LLC Makes New Investment in Novartis AG $NVS

Archford Capital Strategies LLC acquired a new stake in Novartis AG (NYSE:NVS - Free Report) during the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The...

Greenup Street Wealth Management LLC Sells 10,775 Shares of Novartis AG $NVS

Greenup Street Wealth Management LLC trimmed its stake in Novartis AG (NYSE:NVS - Free Report) by 25.7% during the third quarter, according to its most recent 13F filing with the SEC. The...

Voya Investment Management LLC Trims Stock Position in Novartis AG $NVS

Voya Investment Management LLC decreased its position in Novartis AG (NYSE:NVS - Free Report) by 23.0% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities...

DAVENPORT & Co LLC Buys 8,353 Shares of Novartis AG $NVS

DAVENPORT & Co LLC lifted its stake in shares of Novartis AG (NYSE:NVS - Free Report) by 24.8% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange...

Top Healthcare Stocks To Follow Today - December 23rd

UnitedHealth Group, Johnson & Johnson, Intuitive Surgical, Hims & Hers Health, Novartis, Tempus AI, and McKesson are the seven Healthcare stocks to watch today, according to MarketBeat's stock...

Novartis (NYSE:NVS) Sets New 1-Year High - Here's What Happened

Novartis (NYSE:NVS) Reaches New 52-Week High - Here's Why...

Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment includes researching, distributing and selling patented pharmaceuticals. The Sandoz segment focuses on marketing finished dosage form medicines and intermediary products including active pharmaceutical ingredients. The Corporate segment is involved in group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	$1.97	--	--	N/A
Q3 '25	$2.27	$2.25	-1.00%	MISSED
Q2 '25	$2.35	$2.42	2.94%	BEAT
Q1 '25	$2.11	$2.28	7.86%	BEAT
Q4 '24	$1.80	$1.98	9.72%	BEAT

NVS
Novartis AG

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q4 '25

Historical Earnings

Latest NVS News

NVSNovartis AG